Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Lymphoma, Non-Hodgkin 6Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Neoplasm Metastasis 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hodgkin Disease 3Endometrial Neoplasms 3Breast Neoplasms 3Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Mantle-Cell 2Thyroid cancer, follicular 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Thrombocytosis 1Squamous Cell Carcinoma of Head and Neck 1Spinocerebellar Degenerations 1Recurrence 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Multiple Myeloma 1Metastatic Castration-resistant Prostate Cancer 1

Interventions

Carboplatin 156Paclitaxel 154Bevacizumab 96Cyclophosphamide 61Gemcitabine 46olaparib 45Cisplatin 45Topotecan 44niraparib 40liposomal doxorubicin 40pembrolizumab 38Surveys and Questionnaires 33Filgrastim 31Hyperthermic Intraperitoneal Chemotherapy 29Docetaxel 27Taxes 25Blood Specimen Collection 24fludarabine 23Drug Therapy 23Cytoreduction Surgical Procedures 23Peripheral Blood Stem Cell Transplantation 21Etoposide 21Doxorubicin 21Magnetic Resonance Spectroscopy 20durvalumab 17Specimen Handling 17Albumin-Bound Paclitaxel 17Immunoglobulin G 15Disulfides 15Letrozole 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Ovarian Neoplasms × copanlisib × Clear all
NCT03586661 2026-03-11

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
31 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Disease Progression

NCT05082025 2026-01-09

Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations

M.D. Anderson Cancer Center

Phase 2 Terminated
7 enrolled 10 charts
Gynecologic

Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡